What is EpiBiome?
Founded in 2013 in the San Francisco Bay Area, EpiBiome has engineered a sophisticated, high-throughput automated platform for phage discovery. This platform integrates cutting-edge technologies including next-generation sequencing, bioinformatics, machine learning, and directed evolution to accelerate the creation of phage cocktails. These cocktails are designed to target pathogens with significant unmet medical needs. EpiBiome's foundational development was supported by its participation in the inaugural Illumina Accelerator class, followed by its admission into the Johnson & Johnson Innovation JLABS ecosystem, where its automated phage discovery platform was further refined. The company's strategic approach to tackling complex microbial challenges positions it as a key player in the biopharmaceutical innovation landscape.
How much funding has EpiBiome raised?
EpiBiome has raised a total of $12.6M across 3 funding rounds:
Private Equity
$5.6M
Series A
$6M
Debt
$1M
Private Equity (2015): $5.6M, investors not publicly disclosed
Series A (2016): $6M led by SV Tech Ventures and ChinaRock Capital Management
Debt (2016): $1M supported by Silicon Valley Bank
Key Investors in EpiBiome
Silicon Valley Bank
Silicon Valley Bank is a financial institution offering a comprehensive suite of commercial and private banking services, asset management, and investment solutions, with a strong focus on the technology and life sciences sectors.
SV Tech Ventures
SV Tech Ventures is an investment firm that provides capital and strategic support to technology companies, likely focusing on early to growth-stage enterprises.
ChinaRock Capital Management
ChinaRock Capital Management is a registered investment adviser that offers tailored financial strategies, suggesting a focus on diverse investment opportunities across various industries.
What's next for EpiBiome?
With a significant enterprise-level funding context and a recent strategic investment, EpiBiome is poised for accelerated growth and development. The company's robust phage discovery platform, enhanced by machine learning and next-generation sequencing, provides a strong foundation for scaling its operations and advancing its therapeutic pipeline. Future endeavors will likely focus on clinical validation of its phage cocktails and expanding its market reach, leveraging the backing from its strategic investors to address critical public health needs.
See full EpiBiome company page
